Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash & Equivalents (2016 - 2025)

Ultragenyx Pharmaceutical has reported Cash & Equivalents over the past 11 years, most recently at $421.0 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 141.95% to $421.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $421.0 million through Dec 2025, up 141.95% year-over-year, with the annual reading at $421.0 million for FY2025, 141.95% up from the prior year.
  • Cash & Equivalents was $421.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $202.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $480.7 million in Q2 2024 and troughed at $72.6 million in Q3 2023.
  • The 5-year median for Cash & Equivalents is $175.2 million (2024), against an average of $216.9 million.
  • Year-over-year, Cash & Equivalents tumbled 81.47% in 2023 and then skyrocketed 371.0% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $307.6 million in 2021, then tumbled by 56.78% to $132.9 million in 2022, then surged by 60.97% to $214.0 million in 2023, then decreased by 18.69% to $174.0 million in 2024, then soared by 141.95% to $421.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash & Equivalents are $421.0 million (Q4 2025), $202.5 million (Q3 2025), and $176.3 million (Q2 2025).